LEHI, Utah–(BUSINESS WIRE)–Frelii, Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) was notified by
OTC Markets (“OTC”) on May 14, 2019 of recent trading and promotional
activity regarding its common stock. The Company has been informed that
this may have resulted in a higher-than-average trading volume in the
Company’s stock. The Company was informed that newsletter and emails
were sent from a non-affiliated third party source.
The Company had no knowledge of the unauthorized promotional activity
until it was notified by OTC Markets and given a copy of the material.
It was not involved, directly or indirectly, with the creation,
distribution or payment of the promotional materials related to the
Company and its security. The Company had no awareness or editorial
control over the content in the materials.
Upon conducting due diligence inquiries regarding the unauthorized
promotional activity, the Company has determined that the content of the
promotions contains incomplete and unvetted information with speculative
language regarding the Company’s business performance and its shares.
The Company encourages those interested in the Company to rely solely on
information included in its press releases and its filings and
disclosures made with the S.E.C. (through the EDGAR Database) and OTC
After inquiry of management, the Company confirms that its officers,
directors and controlling shareholders (i.e., shareholders owning 10% or
more of the Company’s securities), have not sold or purchased the
Company’s securities within the past 90 days on the open market.
Since December, 2018, the Company has engaged Springboard5 for PR and IR
The Company has not at any point issued shares or convertible
instruments allowing conversion to equity securities at prices
constituting a discount to the current market rate at the time of the
About Frelii, Inc.
Frelii, Inc. is a biotech company that uses human DNA gene sequencing
and artificial intelligence (AI) to assess more than 3.2 billion markers
on the human genome. The results are aligned and leveraged against its
AI, as a means of creating a very strong and powerful data platform for
use by the Health & Wellness, Healthcare, Medical Cannabis and
Pharmaceutical industries. Frelii’s technology generates accurate and
profoundly valuable insight into an individual’s DNA. The company
provides DNA Kit Packages and customized reporting for consumers,
patients and healthcare providers to ensure the ideal treatment, drugs
and dosing are a prime “fit” to the individual. For more information,
please visit www.frelii.com.
Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage
and developing U.S. and international companies. Companies are current
in their reporting and undergo an annual verification and management
certification process. Investors can find Real-Time quotes and market
information for the company on www.otcmarkets.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.